Detection of Cancer Stem Cells Using AC133 Antibody
The cancer stem cell (CSC) model postulates that tumors are formed and maintained by a small population of undifferentiated cells, characterized by unique self-renewal properties and malignant potential. As CSCs survive chemotherapy inducing tumor recurrence, the specific targeting and eradication of these cells represents an important therapeutic challenge in cancer cure. Recent findings on CD133, a pentaspan transmembrane glycoprotein, discuss its application in the identification and isolation of SCs from cancerous tissues. However, the appropriateness of this protein constitutes an ongoing discussion. The expression pattern is debated and several issues highlight the need for additional surface molecules or alternative methods to identify tumor-initiating cells. In this chapter, we will critically summarize progresses and concerns for targeting CSCs via this marker.
KeywordsCancer Stem Cell Stem Cell Marker Cancer Stem Cell Phenotype Brain Tumor Stem Cell Colorectal Cancer Stem Cell
- Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM (2009) Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 69:3382–3389PubMedCrossRefGoogle Scholar
- Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, Chadburn A, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, D’Angelica M, Kemeny N, Lyden D, Rafii S (2008) CD133 expression is not restricted to stem cells, and both CD133+ and CD133− metastatic colon cancer cells initiate tumors. J Clin Invest 118:2111–2120PubMedGoogle Scholar